FDA tacks on new warning to AbbVie's Rinvoq label as safety frets crimp JAK class
The safety problems that continue to plague the JAK class as new data highlight some severe side effects are casting a large shadow over AbbVie …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
